Which type of engineered IL-2 is right for my project: a biased agonist or a pro-cytokine?

It depends on your primary goal. Biased agonists (reduced Treg binding) are ideal for systemic immune boosting, while our Pro-Cytokine strategy is better if your primary concern is minimizing peripheral toxicity by confining activation solely to the tumor microenvironment. We recommend a consultation to determine the optimal starting point.

How does this next-generation IL-2 compare to the older, native HD IL-2 (Proleukin)?

Native high-dose IL-2 is non-specific, causing severe systemic toxicity and preferential Treg expansion. Our engineered agents are designed for high specificity and a superior safety profile, often reducing grade 3/4 toxicity and focusing the immune boost on anti-tumor Teff and NK cells.

IL-2 & Immune Checkpoint Inhibitor (ICI) Combination Therapy Development Service

Creative Biolabs provides an end-to-end solution for developing T_eff-biased or TME-targeted IL-2 therapeutics designed for combination with immune checkpoint inhibitors. We deliver optimized protein engineering, confirm superior functional selectivity through rigorous in vitro assays, and provide a full preclinical pharmacology package for research readiness. Our clients gain a significantly de-risked asset with a superior therapeutic index and benefit from accelerated development timelines due to our integrated manufacturing and quality control systems.

Introduction of IL-2 & ICI Combination Therapy

IL-2, the essential T-cell growth factor, combined with ICIs, is the next frontier to convert 'cold' tumors to 'hot' microenvironments, overcoming the current response rate plateau. Native high-dose IL-2 is severely limited by Treg competition and life-threatening vascular leak syndrome. Next-generation agonists successfully overcome this by engineering T_eff selectivity or, in the latest breakthrough, confining activation to the TME via protease-cleavable Pro-Cytokines. This innovative strategy is scientifically validated to overcome PD-1 resistance in refractory research models.

To effectively translate your scientific concept into a viable preclinical asset, request a consultation.

Fig 1. Combination of ICIs with IL therapy. (OA Literature)

Fig.1 The impact of combinatory ICI/ IL therapy on cellular immunity within TME. ¹

What We Can Offer

Strain and Sequence Optimization

We assess and approve the quality and origin of your cell banks and optimize the codon usage of genes to ensure maximized expression efficiency in selected microbial or mammalian hosts. We also guarantee the stability of strains throughout cell bank generation and large-scale fermentation.

Optimized Process Development

We provide efficient upstream and downstream process development, optimizing culture conditions to maximize yield. Our fermentation process can run in batch, fed-batch, or continuous mode to suit the protein's characteristics and production scale.

Established Quality and Compliance

We operate under a well-established quality system utilizing Quality-by-Design (QbD) and process analytical techniques (PAT). Our production facilities and procedures ensure the highest standards of product quality and safety.

High-Standard Quality Control

Comprehensive high-standard quality control tools are used to quantify and evaluate the quality of your finished IL-2 asset, ensuring consistency and purity for your subsequent research or preclinical studies.

IL-2 & ICI Combination Therapy Development Service at Creative Biolabs

Why Choose Us?

Key Advantages	Unique Features
Pioneering Pro-Cytokine Platform	We are leaders in developing TME-confined ProIL2 assets. By engineering an IL-2Rβ fragment and an MMP-cleavable domain to mask the active mutein, we achieve localized activation, dramatically reducing systemic toxicity and vascular leak.
Superior Selectivity Quantification	We utilize proprietary methodologies for ultra-sensitive T_eff: Treg ratio measurement, ensuring your lead candidate actively promotes intratumoral Treg depletion while boosting cytotoxic lymphocytes.
Integrated PK/PD Strategy	Our service includes built-in pharmacokinetic and pharmacodynamic analysis designed specifically for combination therapies, establishing the optimal dosing schedule for maximum synergy and minimal off-target effects.

Key Advantages

Unique Features

Pioneering Pro-Cytokine Platform

We are leaders in developing TME-confined ProIL2 assets. By engineering an IL-2Rβ fragment and an MMP-cleavable domain to mask the active mutein, we achieve localized activation, dramatically reducing systemic toxicity and vascular leak.

Superior Selectivity Quantification

We utilize proprietary methodologies for ultra-sensitive T_eff: Treg ratio measurement, ensuring your lead candidate actively promotes intratumoral Treg depletion while boosting cytotoxic lymphocytes.

Integrated PK/PD Strategy

Our service includes built-in pharmacokinetic and pharmacodynamic analysis designed specifically for combination therapies, establishing the optimal dosing schedule for maximum synergy and minimal off-target effects.

To fully understand the Creative Biolabs advantage, we invite you to get a quote today.

Customer Reviews

FAQs

Related Services

Antibody and Protein Production

High-yield, high-purity production of any required ancillary proteins, such as specific TME proteases or receptor subunits, for internal validation and screening.

Learn More →

Immuno-Oncology Animal Models

Comprehensive preclinical testing, including syngeneic models, PDX models, and humanized mouse models, is essential for definitive proof-of-concept efficacy studies.